Due to the COVID-19 pandemic, visiting hours are currently restricted. Please visit the COVID-19 page or click here for current visitor information.

Optimizer Implant

CCM Therapy: New Optimizer implant can improve quality of life for CHF patients

 

CAMC is proud to offer the first and only FDA-approved device in the United States for the delivery of cardiac contractility modulation (CCM) therapy – The Optimizer Implant.

Delivered by the Optimizer implant, CCM Therapy can: 

  • Improve quality of life so people with heart failure can get back to doing the activities they love1
  • Work more effectively than medications alone because medications aren’t always enough to manage symptoms
  • Strengthen your heart because its designed to improve contraction of the heart

CCM therapy may be an option for people who aren’t adequately responding to heart failure medications.1

The therapy has been proven to be safe and effective in numerous clinical studies, including several randomized controlled trials, and the results have been published in over 80 articles appearing in leading medical journals.2

The therapy is covered by Medicare and is increasingly covered by commercial insurers.

Delivered by the Optimizer implant, CCM Therapy is a new treatment that:

  • Delivers pulses of energy to the heart
  • May improve contraction of the heart
  • Works differently than medications
  • Is an FDA-approved, minimally-invasive procedure

 Heart failure medications aren’t always enough to help people feel better

  • As heart failure progresses, the heart slowly weakens and is not able to pump with the force required to supply oxygen-rich blood to meet the body’s needs.
  • Symptoms can make everyday activities, such as walking, challenging. They include breathlessness, fatigue, confusion and swelling in the legs.
  • Most people are prescribed medications intended to slow the progression of the disease and manage their symptoms.
  • As the condition progresses, these medications lose their effectiveness and the quality of life for people with heart failure continues to decline.

1 Abraham WT, Kuck KH, Goldsmith RL, et al. A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation. JACC Heart Failure. 6(10), 874-883 (2018).
2 Clinical evidence on file: https://impulse-dynamics.com/providers/clinical-trials/